Hints and tips:
...’s $43bn acquisition of Seagen, a specialist in drugs to treat tumours....
...This echoed complaints from health professionals in Beijing last month, where hospitals ran out of beds, oxygen and drugs after Chinese authorities abandoned their zero-Covid policy of containing the virus...
...The move by the manufacturers followed a ruling this month from the European Medicines Agency that six doses can be extracted from each BioNTech/Pfizer vial rather than five, after health professionals found...
...ExxonMobil’s stock market recovery first began when Pfizer et al announced that they had developed a strong slate of anti-Covid vaccines in November 2020....
...The pharmaceuticals industry is shifting towards slimmed-down companies focused on innovation, including high-priced specialist drugs....
...Adolescents in the US are set to get vaccinated against Covid-19 after the country’s drugs regulator allowed BioNTech/Pfizer’s vaccine to be given to under-16s for the first time....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...Pfizer has previously said it could receive emergency approval for the vaccine from the EMA’s US counterpart, the Food and Drug Administration, this month....
...Germany’s BioNTech and US pharmaceutical company Pfizer said doses of the vaccine would be delivered to the UK in the coming days after the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)...
...Many French cinema owners, who are putting pressure on Cannes to resist Netflix et al, see the streamers’ disruptive attitude as an incursion into their territory....
...Recent medical literature suggests that severe manifestations of COVID19 may be due to tissue damage caused by severe immune dysregulation (Li H, et al; The Lancet; April 2020)....
...Investors and analysts say the company has struggled to regain its mojo since the Obama administration torpedoed a $160bn takeover of the group by Pfizer almost two years ago....
...The company has already started selling professional medical equipment, and a person briefed on its strategy said it was this part of the business that recently applied for wholesale pharmacy licences in...
...Named in the suit are the parent companies and subsidiaries of AstraZeneca, General Electric, Johnson & Johnson, Pfizer and Roche Holding....
...So, for example, the creation and maintenance of neighbourhoods, the cultivation of crops, the provision of medical services, et cetera et cetera....
...Sales of a new breast cancer drug made by Pfizer grew strongly in the second quarter, helping the company beat Wall Street expectations for profits and revenues....
...Steve Yang, the company’s chief operating officer and a veteran of AstraZeneca, Pfizer and the University of California, urges caution....
...There is a certain pressure on AstraZeneca boss Pascal Soriot to come up with successful new drugs, given that he promised a leap in sales when defending the company from a Pfizer takeover bid last year....
...Funds may have sold out of Valeant, Apple et al before the rot set in....
...Gilead’s Truvada, approved for PREP in the US in 2012, is currently the only drug available for this type of treatment, although Viiv, a joint venture between Pfizer and GlaxoSmithKline, is pursuing a rival...
...Maybe we will discover that many managers were smart enough to sell out of Apple, Valeant, Williams et al before their shares tanked....
...His company takes a different approach to many of its rivals who still try to unearth new drugs....
...It’s Pfizer’s second-best selling drug globally and it is the only company selling it in China....
International Edition